Physician profile
Douglas E Lewis
NPI 1225013980
$1,430.26
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $61.07 · 2021: $96.31 · 2022: $366 · 2023: $415 · 2024: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $719 · Long Term Medical Supply Or Device Loan: $64.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.99 |
| Long Term Medical Supply Or Device Loan | $64.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $604.04 | 2022-2024 | |
| Allergan, INC. | $240.74 | 2019-2022 | |
| Rxsight INC | $143.45 | 2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Alcon Vision LLC | $137.87 | 2022 | |
| Biotissue Holdings INC. | $74.09 | 2023 | |
| Carl Zeiss Meditec USA, INC. | $64.25 | 2023 | Cirrus Hd-Oct |
| Novartis Pharmaceuticals Corporation | $31.54 | 2021-2022 | |
| Oyster Point Pharma, INC. | $24.27 | 2022 | |
| Horizon Therapeutics Plc | $21.15 | 2022 | |
| Aerie Pharmaceuticals, INC. | $20.40 | 2019 | |
| Bausch & Lomb Americas INC. | $20.29 | 2023 | Vyzulta |
| Shire North American Group INC | $20.21 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.39 | 2020 | |
| Lilly USA, LLC | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.